Investigators evaluated patient-reported outcomes and tolerability of capivasertib plus abiterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...

Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or ...

CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

A novel scientific method developed at Tel Aviv University promises to accelerate our understanding of the gene PTEN, a key ...